You searched for "choroideal"
Strategies for managing neovascular AMD and DMO in routine clinical care
Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...Genetic profiling for personalised healthcare solutions in AMD – an update
Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...Treatment of diabetic macular oedema
Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...Quality matters in the management of serious eye disorders
The author discusses the first quality standard for serious eye disorders from NICE and takes a look at new care models for enhanced service delivery. Patient backlogs pose risks to patient safety, with research showing that people are losing sight...Broadening of treatment options for potentially blinding retinal conditions
Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...Insights on medical AI for ophthalmology: an update on current perspectives
Artificial intelligence (AI) has immense promise for revolutionising medical practice. Generative AI is a form of AI in which algorithms are trained on datasets that can be used to generate new content, such as text, images or video based on...Belfast briefing: Retina Day roundup from the RCOphth 2024 Annual Congress
Belfast hosted this year’s Royal College of Ophthalmologists’ (RCOphth) Annual Congress, a meeting dedicated to sharing advances, knowledge and clinical practice points in ophthalmic care. This article summarises selected talks by medical and surgical retina specialists during the Retina Subspecialty...
Complement Factor H and Factor H-Like protein are expressed in human RPE cells
The role of inflammation in age-related macular degeneration (AMD) is well documented and the association of AMD with the inflammatory marker C-reactive protein (CRP) and members of the complement system underline the role of complements in AMD. Human complement factor...
Macular pigment and dark adaptation in older population with normal maculas
Macular pigment (MP) such as lutein, zeaxanthin and meso-zeaxanthin are highly concentrated in the fovea. They protect the retina from damage of ambient blue light via antioxidant properties. In older eyes with normal healthy retina, macular pigment optical density (MPOD)...
